The FDA has approved a novel Covid-19 monoclonal antibody drug that appears to target the virus's Omicron form. Monoclonal antibodies are lab-created proteins that imitate the immune system's capacity to combat diseases such as the coronavirus. Eli Lilly and Company's Bebtelovimab is a monoclonal antibody administered through intravenous injection. Bebtelovimab is monoclonal antibodies that can be used to treat persons aged 12 and up who have mild to moderate Covid-19 and are at high risk of developing a Alternative therapy choices aren't accessible or clinically appropriate for those with a severe variant of the illness. Individuals in hospitals or those who require oxygen therapy are not allowed to use it.

Compared to persons who did not take Covid-19, the medication reduced the time someone with Covid-19 had symptoms in a trial with people at low risk of serious illness. Reactions at the infusion site, nausea, and vomiting are all possible adverse effects of bebtelovimab. Scientists have detected uncommon but dangerous complications such as anaphylaxis, infusion-related responses, and hypersensitivity with other monoclonal antibody therapies, and these things might happen with bebtelovimab as well. Because Regeneron's monoclonal antibody therapy and Eli Lilly's previous versions of these medicines looked to no longer effective against the Omicron variation, the FDA banned their usage. Those treatments were aimed at a specific section of the virus that had altered due to Omicron.

Reference: - https://www.nytimes.com/2022/02/11/us/politics/eli-lilly-antibody-treatment-covid.html